Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04722172
Title A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Memorial Sloan Kettering Cancer Center
Indications

chronic lymphocytic leukemia/small lymphocytic lymphoma

chronic lymphocytic leukemia

Therapies

Acalabrutinib + Obinutuzumab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST